<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

John Brancaccio

Committees: Corporate Governance and Nominating Committee, Audit Committee

John Brancaccio, a retired CPA, has served as a director of Trovagene since December 2005. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies.. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) as well as a director of Synergy Pharmaceuticals Inc. and ContraVir Pharmaceuticals, Inc., a subsidiary of Synergy.  Mr. Brancaccio’s chief financial officer experience provides him with valuable financial and accounting expertise which the Board believes qualifies him to serve as a director of our company.


email print
3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message